Published in Int J Chron Obstruct Pulmon Dis on March 08, 2017
Global burden of COPD: systematic review and meta-analysis. Eur Respir J (2006) 7.00
Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet (2011) 2.65
Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol (2006) 2.29
Urine biomarkers predict the cause of glomerular disease. J Am Soc Nephrol (2007) 1.98
Activation of progelatinase A (MMP-2) by neutrophil elastase, cathepsin G, and proteinase-3: a role for inflammatory cells in tumor invasion and angiogenesis. J Cell Physiol (2001) 1.88
Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom (2004) 1.57
Gelsolin expression is necessary for the development of modelled pulmonary inflammation and fibrosis. Thorax (2009) 1.55
Sputum proteomics in inflammatory and suppurative respiratory diseases. Am J Respir Crit Care Med (2008) 1.40
Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol (2006) 1.37
g:Profiler-a web server for functional interpretation of gene lists (2016 update). Nucleic Acids Res (2016) 1.31
Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev (2009) 1.19
Technical aspects and inter-laboratory variability in native peptide profiling: the CE-MS experience. Clin Biochem (2012) 1.18
Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One (2013) 1.12
Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl (2010) 1.12
Technical, bioinformatical and statistical aspects of liquid chromatography-mass spectrometry (LC-MS) and capillary electrophoresis-mass spectrometry (CE-MS) based clinical proteomics: a critical assessment. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.06
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. BMC Cancer (2006) 1.03
Identification of lipocalin and apolipoprotein A1 as biomarkers of chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2010) 0.94
Proteomic analysis in lung tissue of smokers and COPD patients. Chest (2008) 0.94
Matrix elastin: a promising biomarker for chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 0.93
COPD: a multifactorial systemic disease. Ther Adv Respir Dis (2011) 0.92
Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J Proteome Res (2011) 0.91
Immunologic measurement of elastin-derived peptides in human serum. Am Rev Respir Dis (1983) 0.90
Use of proteomic patterns of serum biomarkers in patients with chronic obstructive pulmonary disease: correlation with clinical parameters. Proc Am Thorac Soc (2006) 0.88
Involvement of the MAPK and PI3K pathways in chitinase 3-like 1-regulated hyperoxia-induced airway epithelial cell death. Biochem Biophys Res Commun (2012) 0.88
High-density lipoproteins potentiate α1-antitrypsin therapy in elastase-induced pulmonary emphysema. Am J Respir Cell Mol Biol (2014) 0.86
Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax (2012) 0.86
Physiological conditions can be reflected in human urine proteome and metabolome. Expert Rev Proteomics (2015) 0.86
Alpha1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int J Chron Obstruct Pulmon Dis (2006) 0.85
Proteomic urinary biomarker approach in renal disease: from discovery to implementation. Pediatr Nephrol (2014) 0.85
A proteomic glimpse into human ureter proteome. Proteomics (2015) 0.84
Metabolomic profiling of asthma and chronic obstructive pulmonary disease: A pilot study differentiating diseases. J Allergy Clin Immunol (2015) 0.82
Recent advances in α-1-antitrypsin deficiency-related lung disease. Expert Rev Respir Med (2013) 0.82
Disease Modification in Emphysema Related to Alpha-1 Antitrypsin Deficiency. COPD (2016) 0.81
Urinary proteomic biomarkers to predict cardiovascular events. Proteomics Clin Appl (2015) 0.80
Airway and Extracellular Matrix Mechanics in COPD. Front Physiol (2015) 0.80
Proteomic analysis of alpha-1-antitrypsin in immunoglobulin A nephropathy. Proteomics Clin Appl (2007) 0.80
Gelsolin-mediated activation of PI3K/Akt pathway is crucial for hepatocyte growth factor-induced cell scattering in gastric carcinoma. Oncotarget (2016) 0.79
Pulmonary administration of phosphoinositide 3-kinase inhibitor is a curative treatment for chronic obstructive pulmonary disease by alveolar regeneration. J Control Release (2015) 0.79
Low Serum retinol-binding protein-4 levels in acute exacerbations of chronic obstructive pulmonary disease at intensive care unit admission is a predictor of mortality in elderly patients. J Inflamm (Lond) (2013) 0.79
High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. Front Pharmacol (2016) 0.79
C-Terminal Alpha-1 Antitrypsin Peptide: A New Sepsis Biomarker with Immunomodulatory Function. Mediators Inflamm (2016) 0.78
Peptides in Bronchoalveolar Lavage in Chronic Obstructive Pulmonary Disease. PLoS One (2016) 0.78
Attenuation of Cigarette Smoke-Induced Emphysema in Mice by Apolipoprotein A-1 Overexpression. Am J Respir Cell Mol Biol (2016) 0.78
The Ratio of Free to Bound Desmosine and Isodesmosine May Reflect Emphysematous Changes in COPD. Lung (2015) 0.77
Controversy about alpha 1-antitrypsin in bronchoalveolar lavage fluids. Lancet (1983) 0.76
Well-Known and Less Well-Known Functions of Alpha-1 Antitrypsin. Its Role in Chronic Obstructive Pulmonary Disease and Other Disease Developments. Ann Am Thorac Soc (2016) 0.76
Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD. COPD (2015) 0.76
How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency? PLoS One (2015) 0.80
Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils: putative pathophysiological significance. J Leukoc Biol (2017) 0.75
Quantitative Disease Progression Model of Alpha-1 Proteinase Inhibitor Therapy on CT Lung Density in Patients with Alpha-1 Antitrypsin Deficiency. Br J Clin Pharmacol (2017) 0.75